Fischer Michael B, Wolfram Wendelin, Binder Christoph J, Böhmig Georg A, Wahrmann Markus, Eibl Martha M, Wolf Hermann M
Department of Transfusion Medicine, Medical University of Vienna , Vienna , Austria ; Center of Biomedical Technology, Danube University Krems , Krems an der Donau , Austria.
Department of Transfusion Medicine, Medical University of Vienna , Vienna , Austria.
Front Immunol. 2015 May 6;6:211. doi: 10.3389/fimmu.2015.00211. eCollection 2015.
Common variable immunodeficiency (CVID) is the most common clinically severe primary immunodeficiency and comprises a heterogeneous group of patients with recurrent severe bacterial infections due to the failure to produce IgG antibodies after exposure to infectious agents and immunization. Diagnostic recommendations for antibody failure include assessment of isoagglutinins. We have readdressed this four decades old but still accepted recommendation with up to date methodology.
Anti-A/B IgM- and IgG-antibodies were measured by Diamed-ID Micro Typing, surface plasmon resonance (SPR) using the Biacore(®) device and flow cytometry.
When Diamed-ID Micro Typing was used, CVID patients (n = 34) showed IgG- and IgM-isoagglutinins that were comparable to healthy volunteers (n = 28), while all XLA patients (n = 8) had none. Anti-A/B IgM-antibodies were present in more than 2/3 of the CVID patients and showed binding kinetics comparable to anti-A/B IgM-antibodies from healthy individuals. A correlation could be found in CVID patients between levels of anti-A/B IgM-antibodies and levels of serum IgM and PnP-IgM-antibodies. In contrast in CVID patients as a group ABO antibodies were significantly decreased when assessed by SPR, which correlated with levels of switched memory, non-switched memory and naïve B cells, but all CVID patients had low/undetectable anti-A/B IgG-antibodies.
These results indicate that conventional isoagglutinin assessment and assessment of anti-A/B IgM antibodies are not suited for the diagnosis of impaired antibody production in CVID. Examination of anti-A/B IgG antibodies by SPR provides a useful method for the diagnosis of IgG antibody failure in all CVID patients studied, thus indicating an important additional rationale to start immunoglobulin replacement therapy early in these patients, before post-infectious sequelae develop.
普通变异型免疫缺陷(CVID)是临床上最常见的严重原发性免疫缺陷,包括一组异质性患者,他们因接触感染因子和免疫后无法产生IgG抗体而反复发生严重细菌感染。抗体缺陷的诊断建议包括对同种凝集素的评估。我们采用最新方法重新审视了这一已有四十年历史但仍被接受的建议。
通过Diamed-ID微柱凝胶法、使用Biacore®设备的表面等离子体共振(SPR)和流式细胞术检测抗A/B IgM和IgG抗体。
使用Diamed-ID微柱凝胶法时,CVID患者(n = 34)的IgG和IgM同种凝集素与健康志愿者(n = 28)相当,而所有X连锁无丙种球蛋白血症(XLA)患者(n = 8)均无。超过2/3的CVID患者存在抗A/B IgM抗体,其结合动力学与健康个体的抗A/B IgM抗体相当。在CVID患者中,抗A/B IgM抗体水平与血清IgM和PnP-IgM抗体水平之间存在相关性。相比之下,通过SPR评估时,CVID患者组的ABO抗体显著降低,这与转换记忆B细胞、未转换记忆B细胞和初始B细胞水平相关,但所有CVID患者的抗A/B IgG抗体水平均较低/无法检测到。
这些结果表明,传统的同种凝集素评估和抗A/B IgM抗体评估不适合用于诊断CVID中的抗体产生受损。通过SPR检测抗A/B IgG抗体为所有研究的CVID患者的IgG抗体缺陷诊断提供了一种有用的方法,从而表明在这些患者发生感染后后遗症之前尽早开始免疫球蛋白替代治疗的一个重要额外理由。